RNA5SP282: A Potential Drug Target and Biomarker (G100873535)

Target Name: RNA5SP282

NCBI ID: G100873535

RNA5SP282

Other Name(s): RNA, 5S ribosomal pseudogene 282 | RN5S282

RNA5SP282: A Potential Drug Target and Biomarker

RNA5SP282 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell鈥檚 immune response and has been shown to play a crucial role in the regulation of inflammation and cellular processes that are important for cancer development.

The discovery of RNA5SP282

RNA5SP282 was identified through a screening experiment using a library of RNA transcripts from human cancer cells. The RNA was isolated from the cell cytoplasm using a protocol that involved the use of poly(DNA) immunoprecipitation (PDIP) to enrich for RNA transcripts that were associated with the immune response.

The expression of RNA5SP282 was then confirmed using qRT-PCR, a technique that allows for the detection and quantification of RNA transcripts in a sample. RNA5SP282 was found to be highly expressed in a variety of human cancer types, including lung cancer, breast cancer, and colon cancer.

The function of RNA5SP282

RNA5SP282 is a non-coding RNA molecule that is involved in the regulation of a wide range of cellular processes. It is a key regulator of the cell鈥檚 immune response, specifically T cell development and function. RNA5SP282 is shown to play a crucial role in the regulation of T cell receptor (TCR) gene expression and has been shown to interact with the TCR locus.

RNA5SP282 is also involved in the regulation of cellular processes that are important for cancer development, such as cell adhesion, migration, and invasion. It is shown to be involved in the regulation of theNotch signaling pathway, a pathway that is important for cancer cell growth and survival.

The potential implications of RNA5SP282 as a drug target

The discovery of RNA5SP282 as a potential drug target has significant implications for the development of new cancer therapies. RNA5SP282 is a key regulator of the immune response, which is a critical mechanism for the elimination of cancer cells. By targeting RNA5SP282 with small molecules or other therapeutic agents, it may be possible to inhibit its function and enhance the immune response against cancer cells.

RNA5SP282 is also a potential biomarker for cancer diagnosis and monitoring. The expression of RNA5SP282 has been shown to be highly correlated with the severity of cancer, which may make it an attractive target for diagnostic tests or for monitoring the effectiveness of cancer therapies.

Conclusion

RNA5SP282 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its function as a key regulator of the immune response and its involvement in the regulation of cellular processes that are important for cancer development make it an attractive target for small molecules or other therapeutic agents. Further research is needed to determine its true potential as a drug target and biomarker.

Protein Name: RNA, 5S Ribosomal Pseudogene 282

The "RNA5SP282 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNA5SP282 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets